Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose

References

• McLean E Cogswell M Egli I Wojdyla D de Benoist B Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005 Public Health Nutr 2009 12 4 444 454 18498676
   PubMed Web of Science ®Google Scholar
• Gaskell H Derry S Andrew Moore R McQuay HJ Prevalence of anaemia in older persons: systematic review BMC Geriatr 2008 8 1 18194534
   PubMedGoogle Scholar
• National Institute for Health and Clinical Excellence Anaemia management in people with chronic kidney disease (CKD) NICE Clinical Guideline [Clinical Guideline 114] 2011 Available from: http://guidance.nice.org.uk/cg114
   Google Scholar
• Stoltzfus RJ Defining iron-deficiency anemia in public health terms: a time for reflection J Nutr 2001 131 2S–2S 565S 567S 11160589
   PubMed Web of Science ®Google Scholar
• von Drygalski A Adamson JW Ironing out fatigue Blood 2011 118 3191 3192 21940826
   PubMed Web of Science ®Google Scholar
• Goodnough LT Iron deficiency syndromes and iron-restricted erythropoiesis (CME) Transfusion 2012 52 7 1584 1592 22211566
   PubMed Web of Science ®Google Scholar
• Kohgo Y Ikuta K Ohtake T Torimoto Y Kato J Body iron metabolism and pathophysiology of iron overload Int J Hematol 2008 88 1 7 15 18594779
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (US) Panel on Micronutrients Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc Washington, DC National Academies Press (US) 2001
   Google Scholar
• Shah YM Matsubara T Ito S Yim SH Gonzalez FJ Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency Cell Metab 2009 9 2 152 164 19147412
   PubMed Web of Science ®Google Scholar
• Wang J Pantopoulos K Regulation of cellular iron metabolism Biochem J 2011 434 3 365 381 21348856
   PubMed Web of Science ®Google Scholar
• Shayeghi M Latunde-Dada GO Oakhill JS Identification of an intestinal heme transporter Cell 2005 122 5 789 801 16143108
   PubMed Web of Science ®Google Scholar
• Quigley JG Yang Z Worthington MT Identification of a human heme exporter that is essential for erythropoiesis Cell 2004 118 6 757 766 15369674
   PubMed Web of Science ®Google Scholar
• West AR Oates PS Mechanisms of heme iron absorption: current questions and controversies World J Gastroenterol 2008 14 26 4101 4110 18636652
   PubMed Web of Science ®Google Scholar
• Abboud S Haile DJ A novel mammalian iron-regulated protein involved in intracellular iron metabolism J Biol Chem 2000 275 26 19906 19912 10747949
   PubMed Web of Science ®Google Scholar
• Loréal O Cavey T Bardou-Jacquet E Guggenbuhl P Ropert M Brissot P Iron, hepcidin, and the metal connection Front Pharmacol 2014 5 128 24926268
   PubMed Web of Science ®Google Scholar
• Pak M Lopez MA Gabayan V Ganz T Rivera S Suppression of hepcidin during anemia requires erythropoietic activity Blood 2006 108 12 3730 3735 16882706
   PubMed Web of Science ®Google Scholar
• Fleming RE Iron and inflammation: cross-talk between pathways regulating hepcidin J Mol Med 2008 86 5 491 494 18425494
   PubMed Web of Science ®Google Scholar
• Knutson MD Oukka M Koss LM Aydemir F Wessling-Resnick M Iron release from macrophages after erythrophagocytosis is up-regulated by fer roport in 1 overexpression and down-regulated by hepcidin Proc Natl Acad Sci U S A 2005 102 5 1324 1328 15665091
   PubMed Web of Science ®Google Scholar
• Theurl I Fritsche G Ludwiczek S Garimorth K Bellmann-Weiler R Weiss G The macrophage: a cellular factory at the interphase between iron and immunity for the control of infections Biometals 2005 18 4 359 367 16158228
   PubMed Web of Science ®Google Scholar
• Potdar AA Sarkar J Das NK Computational modeling and analysis of iron release from macrophages PLoS Comput Biol 2014 10 7 e1003701 24991925
   PubMedGoogle Scholar
• Bartnikas TB Andrews NC Fleming MD Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice Blood 2011 117 2 630 637 20956801
   PubMed Web of Science ®Google Scholar
• Funk F Ryle P Canclini C Neiser S Geisser P The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose Arzneimittelforschung 2010 60 6a 345 353 20648926
   PubMed Web of Science ®Google Scholar
• Auerbach M Ballard H Clinical use of intravenous iron: administration, efficacy, and safety Hematology Am Soc Hematol Educ Program 2010 2010 1 338 347 21239816
   PubMed Web of Science ®Google Scholar
• Koskenkorva-Frank TS Weiss G Koppenol WH Burckhardt S The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress Free Radic Biol Med 2013 65 1174 1194 24036104
   PubMed Web of Science ®Google Scholar
• Sohn YS Ghoti H Breuer W The role of endocytic pathways in cellular uptake of plasma non-transferrin iron Haematologica 2012 97 5 670 678 22180428
   PubMed Web of Science ®Google Scholar
• Chao Y Karmali PP Simberg D Role of carbohydrate receptors in the macrophage uptake of dext ran-coated iron oxide nanoparticles Adv Exp Med Biol 2012 733 115 123 22101717
   PubMed Web of Science ®Google Scholar
• Neiser S Wilhelm M Schwarz K Funk F Geisser P Burckhardt S Assessment of dextran antigenicity of intravenous iron products by immunodiffusion assay Port J Nephrol Hypertens 2011 25 219 224
   Google Scholar
• Geisser P Burckhardt S The pharmacokinetics and pharmacodynamics of iron preparat ions Pharmaceutics 2011 3 1 12 33 24310424
   PubMedGoogle Scholar
• Danielson BG Structure, chemistry, and pharmacokinetics of intravenous iron agents J Am Soc Nephrol 2004 15 suppl 2 S93 S98 15585603
   PubMed Web of Science ®Google Scholar
• Bailie GR Mason NA Valaoras TG Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia Hemodial Int 2010 14 1 47 54 19888949
   PubMed Web of Science ®Google Scholar
• Ohgami RS Campagna DR Greer EL Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells Nat Genet 2005 37 11 1264 1269 16227996
   PubMed Web of Science ®Google Scholar
• Geisser P Banke-Bochita J Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose escalation study in volunteers with mild iron-deficiency anaemia Arzneimittelforschung 2010 60 6a 362 372 20648928
   PubMed Web of Science ®Google Scholar
• Geisser P Rumyantsev V Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder Arzneimittelforschung 2010 60 6a 373 385 20648929
   PubMed Web of Science ®Google Scholar
• Beshara S Sörensen J Lubberink M Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography Br J Haematol 2003 120 5 853 859 12614222
   PubMed Web of Science ®Google Scholar
• Breymann C Gliga F Bejenariu C Strizhova N Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia Int J Gynaecol Obstet 2008 101 1 67 73 18234203
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K Lee GH Miller JE Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients Am J Kidney Dis 2009 53 5 823 834 19339087
   PubMed Web of Science ®Google Scholar
• Covic A Mircescu G The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study Nephrol Dial Transplant 2010 25 8 2722 2730 20190247
   PubMed Web of Science ®Google Scholar
• Charytan C Bernardo MV Koch TA Butcher A Morris D Bregman DB Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study Nephrol Dial Transplant 2013 28 4 953 964 23222534
   PubMed Web of Science ®Google Scholar
• Onken JE Bregman DB Harrington RA Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial Nephrol Dial Transplant 2014 29 4 833 842 23963731
   PubMed Web of Science ®Google Scholar
• Qunibi WY Martinez C Smith M Benjamin J Mangione A Roger SD A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients Nephrol Dial Transplant 2011 26 5 1599 1607 20929915
   PubMed Web of Science ®Google Scholar
• Macdougall IC Bock AH Carrera F FIND-CKD Study Investigators FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anemia Nephrol Dial Transplant 2014 29 11 2075 2084 24891437
   PubMed Web of Science ®Google Scholar
• Grimmelt AC Cohen CD Fehr T Serra AL Wuethrich RP Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients Clin Nephrol 2009 71 2 125 129 19203504
   PubMed Web of Science ®Google Scholar
• Anker SD Comin Colet J Filippatos G FAIR-HF Trial Investigators Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 2009 361 25 2436 2448 19920054
   PubMed Web of Science ®Google Scholar
• Van Craenenbroeck EM Conraads VM Greenlaw N The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study Eur J Heart Fail 2013 15 7 756 762 23639779
   PubMed Web of Science ®Google Scholar
• Filippatos G Farmakis D Colet JC Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial Eur J Heart Fail 2013 15 11 1267 1276 23787722
   PubMed Web of Science ®Google Scholar
• Gutzwiller FS Pfeil AM Comin-Colet J Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis Int J Cardiol 2013 168 4 3878 3883 23870642
   PubMed Web of Science ®Google Scholar
• Comin-Colet J Lainscak M Dickstein K The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study Eur Heart J 2013 34 1 30 38 22297124
   PubMed Web of Science ®Google Scholar
• Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al; for the CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency Eur Heart J 2014
   Web of Science ®Google Scholar
• Kulnigg S Stoinov S Simanenkov V A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial Am J Gastroenterol 2008 103 5 1182 1192 18371137
   PubMed Web of Science ®Google Scholar
• Befrits R Wikman O Blomquist L Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life Scand J Gastroenterol 2013 48 9 1027 1032 23889159
   PubMed Web of Science ®Google Scholar
• Kulnigg-Dabsch S Schmid W Howaldt S Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial Inflamm Bowel Dis 2013 19 8 1609 1616 23644823
   PubMed Web of Science ®Google Scholar
• Evstatiev R Marteau P Iqbal T FERGI Study Group FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease Gastroenterology 2011 141 3 846 853 21699794
   PubMed Web of Science ®Google Scholar
• Evstatiev R Alexeeva O Bokemeyer B FERGI Study Group Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease Clin Gastroenterol Hepatol 2013 11 3 269 277 23078888
   PubMed Web of Science ®Google Scholar
• Reim D Kim YW Nam BH FAIRY: a randomized controlled patient-blind phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) to placebo in patients with acute isovolemic anemia after gastrectomy – study protocol for a randomized controlled trial Trials 2014 15 111 24708660
   PubMed Web of Science ®Google Scholar
• Van Wyck DB Mangione A Morrison J Hadley PE Jehle JA Goodnough LT Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial Transfusion 2009 49 12 2719 2728 19682342
   PubMed Web of Science ®Google Scholar
• Herfs R Fleitmann L Kocsis I Treatment of Iron deficiency with or without anaemia with intravenous ferric carboxymaltose in gynaecological practices – a non-interventional study Geburtshilfe Frauenheilkd 2014 74 1 81 88 24741123
   PubMed Web of Science ®Google Scholar
• Christoph P Schuller C Studer H Irion O De Tejada BM Surbek D Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs iron sucrose J Perinat Med 2012 40 5 469 474 22945271
   PubMed Web of Science ®Google Scholar
• Froessler B Collingwood J Hody NA Dekker G Intravenous ferric carboxymaltose for anaemia in pregnancy BMC Pregnancy Childbirth 2014 14 115 24667031
   PubMed Web of Science ®Google Scholar
• Van Wyck DB Martens MG Seid MH Baker JB Mangione A Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial Obstet Gynecol 2007 110 2 pt 1 267 278 17666600
   PubMed Web of Science ®Google Scholar
• Seid MH Derman RJ Baker JB Banach W Goldberg C Rogers R Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial Am J Obstet Gynecol 2008 199 4 435.e1 435.e7. 18928998
   PubMed Web of Science ®Google Scholar
• Pfenniger A Schuller C Christoph P Surbek D Safety and efficacy of high-dose intravenous iron carboxymaltose vs iron sucrose for treatment of postpartum anemia J Perinat Med 2012 40 4 397 402 22752771
   PubMed Web of Science ®Google Scholar
• Keeler BD Simpson JA Ng S The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer Colorectal Dis 2014 16 10 794 800 24916374
   PubMed Web of Science ®Google Scholar
• Malone M Barish C He A Bregman D Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients Obes Surg 2013 23 9 1413 1420 23553506
   PubMed Web of Science ®Google Scholar
• Bisbe E García-Erce JA Díez-Lobo AI Muñoz M Anaemia Working Group España A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery Br J Anaesth 2011 107 3 477 478 21841061
   PubMed Web of Science ®Google Scholar
• Bisbe E Moltó L Arroyo R Muniesa JM Tejero M Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty Br J Anaesth 2014 113 3 402 409 24780615
   PubMed Web of Science ®Google Scholar
• Steinmetz T Tschechne B Harlin O Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia Ann Oncol 2013 24 2 475 482 23071262
   PubMed Web of Science ®Google Scholar
• Rineau E Chaudet A Carlier L Bizot P Lasocki S Ferric carboxymaltose increases epoetin-α response and prevents iron deficiency before elective orthopaedic surgery Br J Anaesth 2014 113 2 296 298 25038162
   PubMed Web of Science ®Google Scholar
• Schatz U Arneth B Siegert G Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations Atheroscler Suppl 2013 14 1 115 122 23357152
   PubMed Web of Science ®Google Scholar
• Allen RP Adler CH Du W Butcher A Bregman DB Earley CJ Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial Sleep Med 2011 12 9 906 913 21978726
   PubMed Web of Science ®Google Scholar
• Hornyak M Scholz H Kiemen A Kassubek J Investigating the response to intravenous iron in restless legs syndrome: an observational study Sleep Med 2012 13 6 732 735 22503006
   PubMed Web of Science ®Google Scholar
• Calvet X Ruíz MÀ Dosal A Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency PLoS One 2012 7 9 e45604 23029129
   PubMed Web of Science ®Google Scholar
• Bhandari S Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice Ther Clin Risk Manag 2011 7 501 509 22241947
   PubMed Web of Science ®Google Scholar
• Muñoz M Gómez-Ramírez S Martín-Montañez E Naveira E Seara J Pavía J Cost of post-operative intravenous iron therapy in total lower limb arthroplasty: a retrospective, matched cohort study Blood Transfus 2014 12 1 40 49 24120595
   PubMed Web of Science ®Google Scholar
• Brock E Braunhofer P Troxler J Schneider H Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data Eur J Health Econ Epub 2014 12
   Web of Science ®Google Scholar
• Fragoulakis V Kourlaba G Goumenos D Konstantoulakis M Maniadakis N Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece Clinicoecon Outcomes Res 2012 4 127 134 22629113
   PubMedGoogle Scholar
• Toblli JE Cao G Olivieri L Angerosa M Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds Nephrol Dial Transplant 2010 25 11 3631 3640 20488820
   PubMed Web of Science ®Google Scholar
• Toblli JE Cao G Oliveri L Angerosa M Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model Arzneimittelforschung 2011 61 7 399 410 21899208
   PubMed Web of Science ®Google Scholar
• Toblli JE Rivas C Cao G Ferric carboxymaltose-mediated attenuation of Doxorubicin-induced cardiotoxicity in an iron deficiency rat model Chemother Res Pract 2014 2014 570241 24876963
   PubMedGoogle Scholar
• Toblli JE Cao G Giani JF Dominici FP Angerosa M Nitrosative stress and apoptosis by intravenous ferumoxytol, iron isomaltoside 1000, iron dextran, iron sucrose, and ferric carboxymaltose in a nonclinical model Drug Res (Stuttg) Epub 2014 7 22
   Google Scholar
• Hussain I Bhoyroo J Butcher A Koch TA He A Bregman DB Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia Anemia 2013 2013 169107 24069536
   PubMedGoogle Scholar
• Onken JE Bregman DB Harrington RA A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia Transfusion 2014 54 2 306 315 23772856
   PubMed Web of Science ®Google Scholar
• Prats M Font R García C Cabré C Jariod M Vea AM Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study BMC Nephrol 2013 14 167 23902731
   PubMed Web of Science ®Google Scholar
• Gravesen E Hofman-Bang J Mace ML Lewin E Olgaard K High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats BMC Nephrol 2013 14 281 24373521
   PubMed Web of Science ®Google Scholar
• Fell LH Zawada AM Rogacev KS Seiler S Fliser D Heine GH Distinct immunologic effects of different intravenous iron preparations on monocytes Nephrol Dial Transplant 2014 29 4 809 822 24523357
   PubMed Web of Science ®Google Scholar
• Maretty L Sharp RE Andersson M Kurtzhals JA Intravenous ferric carboxymaltose accelerates erythropoietic recovery from experimental malarial anemia J Infect Dis 2012 205 7 1173 1177 22357662
   PubMed Web of Science ®Google Scholar
• Malek A In vitro studies of ferric carboxymaltose on placental permeability using the dual perfusion model of human placenta Arzneimittelforschung 2010 60 6a 354 361 20648927
   PubMed Web of Science ®Google Scholar
• Favrat B Balck K Breymann C Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women – PREFER a randomized, placebo-controlled study PLoS One 2014 9 4 e94217 24751822
   PubMed Web of Science ®Google Scholar
• Thompson CA Ferric carboxymaltose approved for iron deficiency anemia Am J Health Syst Pharm 2013 70 17 1458 23943169
   PubMed Web of Science ®Google Scholar